Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic plc (NYSE:MDT) announced four key executive appointments to enhance its healthcare technology leadership. Bob Hopkins becomes head of global strategy, Mei Jiang takes on the role of global digital innovation leader, while Harry 'Skip' Kiil and Mira Sahney will lead the Cranial and Spinal Technologies and Pelvic Health Operating Units, respectively. These appointments aim to bring diverse expertise and accelerate innovation in a rapidly evolving medical technology landscape, furthering Medtronic's mission to deliver transformative healthcare solutions.
Summary not available.
Medtronic plc (NYSE:MDT) will announce its financial results for Q2 FY2022 on November 23, 2021, at approximately 5:45 a.m. CST. The results will cover the quarter ending October 29, 2021. A video webcast to discuss these results will take place at 7:00 a.m. CST on the same day. Medtronic is scheduled to report its Q3 and Q4 results in February and May 2022, respectively. The company, based in Dublin, focuses on healthcare technology solutions, aiming to alleviate pain and restore health.
Summary not available.
Medtronic announced early data from its Intrepid transcatheter mitral valve replacement (TMVR) system at the TCT conference following FDA IDE approval for transfemoral access in the APOLLO trial. Early results show 100% survival and no strokes among the first 15 patients, with a median procedure time of 46 minutes and trace mitral regurgitation in all patients at 30 days. This delivery method may reduce procedural risks. The Intrepid system has been employed in over 350 patients globally, indicating significant interest in its potential for wider clinical use.
Medtronic (NYSE:MDT) announced positive five-year clinical results from the SURTAVI Trial for TAVR patients at intermediate risk. The trial revealed that TAVR with the CoreValve and Evolut platforms demonstrated comparable all-cause mortality rates (30.0% for TAVR vs. 28.7% for SAVR) and lower mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg), ensuring valve performance and safety. The study included 864 TAVR patients compared to 796 surgical patients, highlighting the long-term viability of TAVR in treating severe aortic stenosis.
Medtronic has presented findings from a Patient Preferences study on hypertension treatment at TCT 2021, revealing that patients are willing to accept interventions even with modest blood pressure reductions. The study showed that 76.5% would consider renal denervation (RDN) for a 10 mmHg decrease. Additionally, Medtronic launched the SPYRAL AFFIRM study, focusing on the safety and efficacy of RDN in patients with uncontrolled hypertension and comorbidities. The study will enroll 1,000 patients over three years and is part of a broader effort to establish RDN as a viable treatment option.
Medtronic plc (NYSE: MDT) and Rune Labs have announced a collaboration aimed at enhancing patient care through neurostimulation data analysis. The project will utilize Rune's software to integrate and analyze data from Medtronic's Percept™ PC Neurostimulator and the StrivePD Apple Watch app, focusing on Parkinson's disease treatment. This innovative approach will enable continuous monitoring of local field potentials, potentially guiding personalized treatment decisions. The initiative includes a 12-month monitoring plan for up to 1,000 patients across selected DBS centers.
Medtronic plc (NYSE:MDT) has appointed Dr. Austin L. Chiang as the Chief Medical Officer (CMO) for its Gastrointestinal (GI) business. Dr. Chiang, an accomplished gastroenterologist, will offer strategic guidance on clinical communications, risk management, and patient safety throughout the product lifecycle. His expertise includes advanced endoscopy and obesity medicine, enhancing Medtronic's innovation in GI care. Dr. Chiang will continue his clinical practice at Jefferson Health while contributing to product development and clinical trials at Medtronic.
Medtronic (NYSE: MDT) reported promising results from a study involving 3,211 pediatric patients with type 1 diabetes using the MiniMed™ 780G system. The one-year data revealed a 74% average Time in Range and 82% overnight Time in Range, outperforming clinical guidelines. The study demonstrated that 75.3% of users achieved a Glucose Management Indicator (GMI) below 7%. The MiniMed 780G system’s advanced hybrid closed-loop algorithm adapts insulin delivery every five minutes, leading to improved glycemic control and personalization, making it an effective choice for managing diabetes in children.